Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Slides:

Advertisements

Similar presentations

Nimotuzumab and radiotherapy in children and adolescents with brain stem glioma: Preliminary results from a Phase II study. T. Crombet 1, R. Cabanas 2,

Advertisements

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

13th Annual Hematology & Breast Cancer Update Update in Lymphoma

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.

Presented By Patrick Wen at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Meta-analysis of trials of radiotherapy in DCIS Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.

Tang G et al. Proc SABCS 2010;Abstract S4-9.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Phase II Trial of Continuous Course Re- irradiation Concurrent with Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of The Head.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

Eastern cooperative oncology group Impact of Bevacizumab Dose Reduction on Clinical Outcomes for Patients Treated on the Eastern Cooperative Oncology Group’s.

1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.

Phase Ⅱ Trial of Docetaxel and Cisplatin Neoadjuvant Chemotherapy Followed by Intensity-modulated Radiotherapy with Concurrent Cisplatin in Locally Advanced.

The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.

Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.

Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.

EARLY PROGRESSION IN PATIENTS WITH HIGH-RISK SOFT TISSUE SARCOMAS AN ANALYSIS FROM A PHASE III RANDOMIZED PROSPECTIVE TRIAL (EORTC 62961/ESHO) OF NEOADJUVANT.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

GBM – Oncological Management Dr H Lord Consultant Clinical Oncologist.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC randomised trial From.

Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 Friedberg.

National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.

SNDA # GLIADEL® WAFER (Polifeprosan 20 with Carmustine Implant) APPLICANT: GUILFORD PHARMACEUTICALS ODAC: December 6, 2001 Medical Reviewer: Alla.

Hysterectomy after Chemoradiotherapy for Stage Ib2 and IIb Cervical Cancer Vivek Nama UHBT.

INTERGROUP STUDY 0148 BMS CA Effect of TAXOL® (paclitaxel) and Doxorubicin Dose on Disease Free and Overall Survival of Patients with Node Positive.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

Date of download: 5/31/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Outcome of Salvage Total Laryngectomy Following Organ.

Presented By Michael Overman at 2016 ASCO Annual Meeting

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.

Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.

Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

R3 이운주/Prof 맹치훈. Introduction Pancreatic adenocarcinoma is most lethal cancer, with a 5-year survival rate of less than 5%. Relapsed occurs in 80-85%

12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

Summary Author: Dr. C. Tom Kouroukis, MD MSc FRCPC

Presented By James Hill at 2016 ASCO Annual Meeting

CCO Independent Conference Highlights

Securing the cure in resectable lung cancer

Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting

Highlights: Myeloma Oral Session

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Luca Malorni at 2017 ASCO Annual Meeting

S1207: Phase III randomized, placebo-controlled trial adding 1 year of everolimus to adjuvant endocrine therapy for patients with high-risk, HR+, HER2-

Joensuu H et al. Proc ASCO 2011;Abstract LBA1.

Presented By Mathias Rummel at 2016 ASCO Annual Meeting

ACT II: The Second UK Phase III Anal Cancer Trial

Background: Gene Expression

Figure 3 Overall survival, according to treatment group

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Presented By Andrew Evens at 2016 ASCO Annual Meeting

Presentation transcript:

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting

Slide 2 Presented By Jan Buckner at 2014 ASCO Annual Meeting

No Disclosures Presented By Jan Buckner at 2014 ASCO Annual Meeting

Responses to Chemotherapy in Recurrent Low-grade Glioma Patients Presented By Jan Buckner at 2014 ASCO Annual Meeting

PCV for newly diagnosed Grade 2 O/OA Presented By Jan Buckner at 2014 ASCO Annual Meeting

R9802 SCHEMA Presented By Jan Buckner at 2014 ASCO Annual Meeting

Key Eligibility Criteria Presented By Jan Buckner at 2014 ASCO Annual Meeting

Pretreatment Patient Characteristics Demographic Factors Presented By Jan Buckner at 2014 ASCO Annual Meeting

Pretreatment Patient Characteristics Functional Status Presented By Jan Buckner at 2014 ASCO Annual Meeting

Pretreatment Patient Characteristics Surgery and Histology Presented By Jan Buckner at 2014 ASCO Annual Meeting

Data Maturity Presented By Jan Buckner at 2014 ASCO Annual Meeting

Slide 12 Presented By Jan Buckner at 2014 ASCO Annual Meeting

ASCO 2014: Progression-Free Survival Presented By Jan Buckner at 2014 ASCO Annual Meeting

Progression-Free Survival ASCO 2014 Presented By Jan Buckner at 2014 ASCO Annual Meeting

Slide 15 Presented By Jan Buckner at 2014 ASCO Annual Meeting

ASCO 2014: Overall Survival Presented By Jan Buckner at 2014 ASCO Annual Meeting

Overall Survival ASCO 2014 Presented By Jan Buckner at 2014 ASCO Annual Meeting

Salvage Treatment Presented By Jan Buckner at 2014 ASCO Annual Meeting

Cox Proportional Hazards Model for Progression Free Survival (n=251) Presented By Jan Buckner at 2014 ASCO Annual Meeting

Cox Proportional Hazards Model for Overall Survival (n=251) Presented By Jan Buckner at 2014 ASCO Annual Meeting

Constitutional Toxicity Presented By Jan Buckner at 2014 ASCO Annual Meeting

Hematologic Toxicity Presented By Jan Buckner at 2014 ASCO Annual Meeting

Gastrointestinal Tract Toxicity Presented By Jan Buckner at 2014 ASCO Annual Meeting

Late Radiotherapy Toxicity Presented By Jan Buckner at 2014 ASCO Annual Meeting

Categorical Change in MMSE Score by Treatment Arm Presented By Jan Buckner at 2014 ASCO Annual Meeting

Conclusions (Survival) Presented By Jan Buckner at 2014 ASCO Annual Meeting

Conclusions (Prognostic Variables) Presented By Jan Buckner at 2014 ASCO Annual Meeting

Conclusions (Toxicity) Presented By Jan Buckner at 2014 ASCO Annual Meeting

Conclusions (Trial Conduct) Presented By Jan Buckner at 2014 ASCO Annual Meeting

Future Plans Presented By Jan Buckner at 2014 ASCO Annual Meeting

Acknowledgements Presented By Jan Buckner at 2014 ASCO Annual Meeting

Slide 32 Presented By Jan Buckner at 2014 ASCO Annual Meeting

Back Up Slides Presented By Jan Buckner at 2014 ASCO Annual Meeting

Radiotherapy Review Presented By Jan Buckner at 2014 ASCO Annual Meeting

Chemotherapy Review Presented By Jan Buckner at 2014 ASCO Annual Meeting